This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

RAPT Therapeutics Crescita futura

Criteri Future verificati 0/6

Si prevede che gli utili di RAPT Therapeutics diminuiranno del 29% all'anno, mentre si prevede che il fatturato annuo crescerà del 84.4% all'anno. Si prevede che l'EPS diminuirà del 15.4% all'anno.

Informazioni chiave

-29.0%

Tasso di crescita degli utili

-15.44%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	22.7%
Tasso di crescita dei ricavi	84.4%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	03 Mar 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

Jan 20

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

Feb 21

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Sep 12

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

May 10

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Feb 07

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Oct 12

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Oct 15

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jun 08

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

Mar 15

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:RAPT - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	N/A	-220	-183	N/A	4
12/31/2027	N/A	-162	-142	N/A	4
12/31/2026	N/A	-91	-99	N/A	4
12/31/2025	N/A	-83	-79	N/A	4
9/30/2025	N/A	-106	-87	-87	N/A
6/30/2025	N/A	-106	-92	-92	N/A
3/31/2025	N/A	-117	-109	-109	N/A
12/31/2024	N/A	-130	-83	-83	N/A
9/30/2024	N/A	-107	-101	-101	N/A
6/30/2024	N/A	-120	-105	-105	N/A
3/31/2024	N/A	-118	-106	-106	N/A
12/31/2023	N/A	-117	-98	-97	N/A
9/30/2023	N/A	-109	-93	-92	N/A
6/30/2023	N/A	-99	-89	-87	N/A
3/31/2023	1	-93	-75	-74	N/A
12/31/2022	2	-84	-72	-71	N/A
9/30/2022	2	-79	-70	-69	N/A
6/30/2022	3	-76	-65	-64	N/A
3/31/2022	3	-73	-63	-63	N/A
12/31/2021	4	-69	-62	-61	N/A
9/30/2021	4	-64	-56	-56	N/A
6/30/2021	5	-60	-54	-53	N/A
3/31/2021	5	-56	-46	-46	N/A
12/31/2020	5	-53	-41	-40	N/A
9/30/2020	4	-53	-31	-31	N/A
6/30/2020	2	-49	-33	-33	N/A
3/31/2020	1	-47	-36	-36	N/A
12/31/2019	N/A	-43	-36	-35	N/A
9/30/2019	N/A	-39	-42	-39	N/A
6/30/2019	N/A	-40	N/A	-36	N/A
3/31/2019	N/A	-37	N/A	-34	N/A
12/31/2018	N/A	-36	N/A	-33	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che RAPT rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che RAPT rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che RAPT rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che RAPT non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che RAPT non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di RAPT è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/03/05 07:29
Prezzo dell'azione a fine giornata	2026/03/02 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github, abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

RAPT Therapeutics, Inc. è coperta da 17 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Leiyang Wang	Barclays
Etzer Darout	Barclays
Gao Yi Chen	Berenberg

This company has been acquired

RAPT Therapeutics Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 18% to US$18.14

Price target decreased by 21% to US$33.63

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$50.29

Recent updates

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

RAPT Therapeutics, Inc. Announces William Ho Leaves as Chief Medical Officer on December 31, 2025

RAPT Therapeutics, Inc. Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies

RAPT Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.00002 million.

RAPT Therapeutics, Inc. and Shanghai Jeyou Pharmaceutical Co., Ltd. Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy

We're Keeping An Eye On RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate

RAPT Therapeutics, Inc. Announces Board and Committee Appointments

RAPT Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Minimum Closing Bid Price Rule

RAPT Therapeutics, Inc., Annual General Meeting, May 29, 2025

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Wendye R. Robbins Does Not Stand for Election as Director of Rapt Therapeutics, Inc

Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904

RAPT Therapeutics, Inc. Announces Board Changes

RAPT Therapeutics, Inc. announced that it expects to receive $149.976555 million in funding from a group of investors

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Rapt Therapeutics Approves Reduction to Their Workforce

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Price target decreased by 18% to US$18.14

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

RAPT Therapeutics, Inc., Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Price target decreased by 21% to US$33.63

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon (RPT193) in Atopic Dermatitis and its Phase 2a Trial in Asthma

New major risk - Revenue and earnings growth

RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations

RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy

New major risk - Revenue and earnings growth

New minor risk - Share price stability

RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

New major risk - Revenue and earnings growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

First quarter 2023 earnings released: US$0.77 loss per share (vs US$0.69 loss in 1Q 2022)

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

Insider recently bought US$98k worth of stock

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Insufficient new directors

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.63 loss per share (vs US$0.63 loss in 3Q 2021)

Chief Medical Officer notifies of intention to sell stock

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$50.29

Price target decreased to US$53.00

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$77k worth of stock

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer exercised options and sold US$69k worth of stock

Chief Scientific Officer exercised options and sold US$65k worth of stock

Third quarter 2021 earnings released: US$0.63 loss per share (vs US$0.60 loss in 3Q 2020)